Acumen Pharmaceuticals Inc

Research Acumen Pharmaceuticals Inc (ABOS) on Bullrun: market cap USD 200.07M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABOS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 200.07M
• Financial periodFY2025
• Net income-USD 121.34M
• Free cash flow-USD 115.63M

Valuation Snapshot

latest market cap is USD 200.07M.

About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc.

Frequently asked questions

What is Acumen Pharmaceuticals Inc's market cap?

Acumen Pharmaceuticals Inc's market capitalization is USD 200.07M.

What does Acumen Pharmaceuticals Inc do?

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.